34878 Federal Register / Vol. 83, No. 141 / Monday, July 23, 2018 / Notices 

3 ‘‘Dispensing’’ a controlled substance includes 

‘‘prescribing’’ and ‘‘administering’’ it. Miss. Code 

Ann. § 41–29–105(j) (West, Westlaw current with 

laws from the 2018 Regular Session). 

defined the term ‘‘practitioner’’ to mean 

‘‘a physician . . . or other person 

licensed, registered, or otherwise 

permitted, by . . . the jurisdiction in 

which he practices . . . , to distribute, 

dispense, . . . [or] administer . . . a 

controlled substance in the course of 

professional practice.’’ 21 U.S.C. 

802(21). Second, in setting the 

requirements for obtaining a 

practitioner’s registration, Congress 

directed that ‘‘[t]he Attorney General 

shall register practitioners . . . if the 

applicant is authorized to dispense . . . 

controlled substances under the laws of 

the State in which he practices.’’ 21 

U.S.C. 823(f). Because Congress has 

clearly mandated that a practitioner 

possess State authority in order to be 

deemed a practitioner under the CSA, 

the DEA has held repeatedly that 

revocation of a practitioner’s registration 

is the appropriate sanction whenever he 

is no longer authorized to dispense 

controlled substances under the laws of 

the State in which he practices. See, 

e.g., Hooper, supra, 76 FR at 71,371–72; 

Sheran Arden Yeates, M.D., 71 FR 

39,130, 39,131 (2006); Dominick A. 

Ricci, M.D., 58 FR 51,104, 51,105 (1993); 

Bobby Watts, M.D., 53 FR 11,919, 11,920 

(1988); Blanton, supra, 43 FR at 27,617. 

According to Mississippi statute, 

‘‘Every person who desires to practice 

dentistry . . . in this state must obtain 

a license to do so.’’ Miss. Code Ann. 

§ 73–9–1 (West, Westlaw current with 

laws from the 2018 Regular Session). 

Further, ‘‘[e]very person who . . . 

dispenses any controlled substance 

within this state . . . must obtain a 

registration issued by . . . the State 

Board of Dental Examiners . . . in 

accordance with its rules and the law of 

this state.’’ Miss. Code Ann. § 41–29– 

125(1)(a) (West, Westlaw current with 

laws from the 2018 Regular 

Session).3 See also Miss. Code Ann. 

§ 73–9–53 (West, Westlaw current with 

laws from the 2018 Regular Session) 

(authorizing Mississippi pharmacists to 

fill prescriptions only of ‘‘legally 

licensed and registered dentists of this 

state for any drugs to be used in the 

practice of dentistry’’) and Miss. Admin. 

Code 30–2301:1.35(1) (West, current 

through the Mississippi Administrative 

Rules Listing of Filings, dated May 

2018) (legally licensed and registered 

dentists may write prescriptions for any 

drugs to be used in the practice of 

dentistry). 

Here, the undisputed evidence in the 

record is that Registrant currently lacks 

authority to practice dentistry and 

handle controlled substances in 

Mississippi. As already discussed, only 

a legally licensed and registered dentist 

may dispense a controlled substance or 

any drug to be used in the practice of 

dentistry in Mississippi. Thus, since 

Registrant lacks authority to practice 

dentistry in Mississippi, and is not 

registered in Mississippi to handle 

controlled substances, I will order that 

Registrant’s DEA registration be 

revoked. 

Order 

Pursuant to 28 CFR 0.100(b) and the 

authority thus vested in me by 21 U.S.C. 

824(a), I order that DEA Certificate of 

Registration No. FB0508993 issued to 

Kenneth C. Beal, Jr., D.D.S., be, and it 

hereby is, revoked. This Order is 

effective August 22, 2018. 

Dated: July 9, 2018. 

Uttam Dhillon, 

Acting Administrator. 

[FR Doc. 2018–15743 Filed 7–20–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Fresenius Kabi USA, LLC 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before August 22, 2018. Such persons 

may also file a written request for a 

hearing on the application on or before 

August 22, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All request for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: 

The Attorney General has delegated 

his authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on June 

21, 2018, Fresenius Kabi USA, LLC, 

3159 Staley Road, Grand Island, New 

York 14072–2028 applied to be 

registered as an importer of the 

following basic class of controlled 

substance: 

Controlled substance Drug code Schedule 

Remifentanil ............................................................................................................................................................. 9739 II 


amozie on DSK3GDR082PROD with NOTICES1
Federal Register / Vol. 83, No. 141 / Monday, July 23, 2018 / Notices 34879 

The company plans to import the 

listed controlled substance for narcotic 

material for bulk manufacture. 

Dated: July 12, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–15750 Filed 7–20–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Applications: Shertech Laboratories, 

LLC 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before August 22, 2018. Such persons 

may also file a written request for a 

hearing on the application on or before 

August 22, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All request for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on April 

23, 2018, Shertech Laboratories, LLC, 

1185 Woods Chapel Road, Duncan 

South Carolina 29334 applied to be 

registered as an importer of the 

following basic class of controlled 

substance: 

Controlled substance Drug 

Code Schedule 

Cocaine ........................ 9041 II 

The company plans to import 

synthetic derivatives of the listed 

controlled substance in bulk form to 

conduct clinical trials. 

Approval of permit applications will 

occur only when the registrant’s activity 

is consistent with what is authorized 

under to 21 U.S.C.952 (a)(2). 

Authorization will not extend to the 

import of FDA approved or nonapproved finished dosage forms for 

commercial sale. 

Dated: July 12, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–15713 Filed 7–20–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Fisher Clinical Services, 

Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before August 22, 2018. Such persons 

may also file a written request for a 

hearing on the application on or before 

August 22, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on June 5, 

2018, Fisher Clinical Services, 700A–C 

Nestle Way, Breinigsville, PA 18031– 

1522 applied to be registered as an 

importer of the following basic class of 

controlled substance: 

Controlled substance Drug 

code Schedule 

Psilocybin ..................... 7437 I 

The company plans to import the 

listed controlled substance for clinical 

trials. 

Dated: July 12, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–15667 Filed 7–20–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Registration 

ACTION: Notice of registration. 

SUMMARY: The registrant listed below 

has applied for and been granted 

registration by the Drug Enforcement 

Administration (DEA) as an importer of 

various classes of schedule I or II 

controlled substances. 

SUPPLEMENTARY INFORMATION: 

The company listed below applied to 

be registered as an importer of various 

basic classes of controlled substances. 

Information on the previously published 

notice is listed in the table below. No 

comments or objections were submitted 


amozie on DSK3GDR082PROD with NOTICES1